151 related articles for article (PubMed ID: 11746820)
41. Calcitonin receptor down-regulation relates to calcitonin resistance in mature mouse osteoclasts.
Wada S; Udagawa N; Nagata N; Martin TJ; Findlay DM
Endocrinology; 1996 Mar; 137(3):1042-8. PubMed ID: 8603572
[TBL] [Abstract][Full Text] [Related]
42. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
43. Autocrine regulation of osteoclast formation and bone resorption by IL-1 alpha and TNF alpha.
Tani-Ishii N; Tsunoda A; Teranaka T; Umemoto T
J Dent Res; 1999 Oct; 78(10):1617-23. PubMed ID: 10520966
[TBL] [Abstract][Full Text] [Related]
44. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
[TBL] [Abstract][Full Text] [Related]
45. IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
Kitami S; Tanaka H; Kawato T; Tanabe N; Katono-Tani T; Zhang F; Suzuki N; Yonehara Y; Maeno M
Biochimie; 2010 Apr; 92(4):398-404. PubMed ID: 20045440
[TBL] [Abstract][Full Text] [Related]
46. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
47. Characterization of mouse cathepsin K gene, the gene promoter, and the gene expression.
Li YP; Chen W
J Bone Miner Res; 1999 Apr; 14(4):487-99. PubMed ID: 10234569
[TBL] [Abstract][Full Text] [Related]
48. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts.
Vääräniemi J; Halleen JM; Kaarlonen K; Ylipahkala H; Alatalo SL; Andersson G; Kaija H; Vihko P; Väänänen HK
J Bone Miner Res; 2004 Sep; 19(9):1432-40. PubMed ID: 15312243
[TBL] [Abstract][Full Text] [Related]
49. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
Han SY; Lee KH; Kim YK
Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
[TBL] [Abstract][Full Text] [Related]
50. The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation/function.
Rajapurohitam V; Chalhoub N; Benachenhou N; Neff L; Baron R; Vacher J
Bone; 2001 May; 28(5):513-23. PubMed ID: 11344051
[TBL] [Abstract][Full Text] [Related]
51. Cathepsin K inhibitors as treatment of bone metastasis.
Le Gall C; Bonnelye E; Clézardin P
Curr Opin Support Palliat Care; 2008 Sep; 2(3):218-22. PubMed ID: 18685424
[TBL] [Abstract][Full Text] [Related]
52. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma.
Littlewood-Evans AJ; Bilbe G; Bowler WB; Farley D; Wlodarski B; Kokubo T; Inaoka T; Sloane J; Evans DB; Gallagher JA
Cancer Res; 1997 Dec; 57(23):5386-90. PubMed ID: 9393764
[TBL] [Abstract][Full Text] [Related]
53. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
54. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine.
Li H; Miyahara T; Tezuka Y; Namba T; Suzuki T; Dowaki R; Watanabe M; Nemoto N; Tonami S; Seto H; Kadota S
Biol Pharm Bull; 1999 Apr; 22(4):391-6. PubMed ID: 10328560
[TBL] [Abstract][Full Text] [Related]
55. Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.
Sasaki T
Microsc Res Tech; 2003 Aug; 61(6):483-95. PubMed ID: 12879416
[TBL] [Abstract][Full Text] [Related]
56. Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo.
Kozloff KM; Quinti L; Patntirapong S; Hauschka PV; Tung CH; Weissleder R; Mahmood U
Bone; 2009 Feb; 44(2):190-8. PubMed ID: 19007918
[TBL] [Abstract][Full Text] [Related]
57. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of Ulmus davidiana Planch (Ulmaceae) on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts.
Kim KW; Park JS; Kim KS; Jin UH; Kim JK; Suh SJ; Kim CH
Phytother Res; 2008 Apr; 22(4):511-7. PubMed ID: 18338784
[TBL] [Abstract][Full Text] [Related]
59. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.
Gravallese EM; Manning C; Tsay A; Naito A; Pan C; Amento E; Goldring SR
Arthritis Rheum; 2000 Feb; 43(2):250-8. PubMed ID: 10693863
[TBL] [Abstract][Full Text] [Related]
60. Cystatin B as an intracellular modulator of bone resorption.
Laitala-Leinonen T; Rinne R; Saukko P; Väänänen HK; Rinne A
Matrix Biol; 2006 Apr; 25(3):149-57. PubMed ID: 16321512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
